Наркоманное повреждение печени вторично для ритуксимаба.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Armendariz-Pineda Samantha Melanie, Vargas-Beltran Andres Manuel, Corredor-Nassar Maria Juliana, Gamboa-Domínguez Armando, Santos-Reyes David Arturo, Cordova-Gallardo Jacqueline
Аннотация
Оригинал публикации
Drug-induced liver injury secondary to rituximab use.
DILI: drug-induced liver injury, HBV: Hepatitis B virus, LFT: liver function test, RRMS: Relapsing-remitting multiple sclerosis, UDCA: ursodeoxycholic acid. Rituximab is a human chimeric monoclonal antibody that targets CD20 on B cells. The incidence of rituximab-associated drug-induced liver injury (DILI) is 19 cases per 100 000 people annually. This condition is characterized by a rapid increase in aminotransferase levels and hepatocellular injury, primarily due to reactivation of the hepatitis B virus (HBV). Nevertheless, there have been rare cases of DILI occurring in the absence of HBV reactivation. This case presents a 25-year-old male with relapsing-remitting multiple sclerosis (RRMS) that was treated with rituximab. After treatment, the patient demonstrated a hepatocellular damage pattern and biopsy confirmed the diagnosis. Following the administration of ursodeoxycholic acid (UDCA), the patient's liver function tests (LFTs) returned to normal levels, demonstrating that DILI from rituximab can occur after any infusion, regardless of therapy duration or dosage.